ClinicalTrials.gg
CompletedNCT07098585Updated Aug 1, 2025

To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.

A Phase 1 interventional study of Lisdexamfetamine capsule and Elvanse® (Lisdexamfetamine dimesylate capsules, hard) in Attention Deficit/Hyperactivity Disorder (ADHD), sponsored by Humanis Saglık Anonim Sirketi. Completed at 1 site in India. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by Humanis Saglık Anonim Sirketi · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
26th of 51
48 · median 48
Started
2025
the only one that year
Phase 1
2 of 51
none open now
Registered
51st of 51
by date

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 26th largest by enrollment, is the only one that started in 2025, is one of 2 in phase 1, and was the 51st registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

An open label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study in healthy adult human subjects under fasting conditions.

03

Conditions studied

  • Attention Deficit/Hyperactivity Disorder (ADHD)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 to 55 years old, both inclusive.
  • Gender: Male and/or non-pregnant, non-lactating female.

A. Female of had a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days of the first dose of study medication. They used an acceptable form of . For female of child-bearing potential, acceptable forms of contraception included the following:

i. Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or ii. Barrier methods containing or used in conjunction with a spermicidal agent, or iii. Surgical sterilization or iv. Practicing sexual abstinence throughout the course of the study.

B. Female was not considered of child-bearing potential if one of the following was reported and documented on the medical history:

i. with spontaneous amenorrhea for at least one year, or ii. Spontaneous amenorrhea for more than 6 months and less than one year with Serum Follicular Stimulating Hormone (FSH) level > 40 mIU/mL, or iii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or iv. Total hysterectomy and an absence of bleeding for at least 3 months.

  • : 18.5 to 30.0 kg/m2, both inclusive; BMI value was rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5).
  • Non-smokers and non-tobacco user (i.e. had no past history of smoking and tobacco consuming for at least one year prior to study).
  • Able to communicate effectively with study personnel.
  • Willing to provide written to participate in the study.
  • All volunteers were assessed as normal and healthy by the principal investigator, co-investigator, or physician during the pre-study safety assessment conducted within 28 days of the first dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • History of allergic responses to Lisdexamfetamine Dimesylate, sympathomimetic amines or other related drugs, or any of its formulation ingredients.
  • Had significant diseases or abnormal findings during screening [medical history, physical examination (clinical examination), laboratory evaluations, recording, echocardiography, gynecological history and examination (including pelvic examination and routine breast examination) (for female volunteers)].
  • Any disease or condition like diabetes, psychosis or others, which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system.
  • History or presence of bronchial asthma.
  • Used any hormone replacement therapy within 3 months prior to the first dose of study medication.
  • Used any depot injection or implant of any drug within 3 months prior to the first dose of study medication.
  • Used CYP enzyme inhibitors or inducers within 30 days prior to the first dose of study medication.
  • History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
  • History of difficulty with donating blood or difficulty in accessibility of veins.
  • A positive hepatitis screen (includes subtypes B \& C).
  • A positive test result for antibody.
  • Volunteers who had received a known drug within seven elimination half-life of the administered drug prior to the first dose of study medication.
  • Volunteers who had donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or >200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever was greater.
  • History of difficulty in swallowing or of any gastrointestinal disease, which could affect drug absorption.
  • Intolerance to venipuncture
  • Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the volunteer's participation in this study.
  • Institutionalized volunteers.
  • Used any prescribed medications (including monoamine oxidase inhibitors) within 14 days prior to the first dose of study medication.
  • Used any OTC products, vitamin and herbal products, etc., within 7 days prior to the first dose of study medication.
  • Used grapefruit and grapefruit containing products within 7 days prior to the first dose of study medication.
  • Ingestion of any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.), recreational drugs, alcohol or other alcohol containing products within 48 hours prior to the first dose of study medication.
  • Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the first dose of study medication.
  • Volunteer had clinically significant ECG abnormalities.
  • Volunteer had sitting systolic blood pressure less than 100 mmHg or greater than 140 mmHg or sitting diastolic blood pressure less than 60 mmHg or greater than 90 mmHg and pulse rate less than 60 or greater than 100 per minute during screening.
  • Volunteer had history of Hyperthyroidism or thyrotoxicosis.
  • Volunteer had history of Glaucoma.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Lisdexamfetamine capsule

    Lisdexamfetamine 70 mg capsule

    Drug: Lisdexamfetamine capsule · Drug: Elvanse® (Lisdexamfetamine dimesylate capsules, hard)

  • Active comparator
    Elvanse® (Lisdexamfetamine dimesylate capsules, hard)

    Elvanse® (Lisdexamfetamine dimesylate 70 mg capsules, hard)

    Drug: Lisdexamfetamine capsule · Drug: Elvanse® (Lisdexamfetamine dimesylate capsules, hard)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum measured plasma concentration (Cmax)

    90% confidence intervals for the geometric least squares mean ratio of (T/R) will be calculated and reported for Cmax

    Time frame: 72 hours

  2. Area under the plasma concentration versus time curve from the zero time point to the last quantifiable concentration (AUCt)

    90% confidence intervals for the geometric least squares mean ratio of (T/R) will be calculated and reported for AUCt

    Time frame: 72 hours

Secondary outcomes

  1. The area under the plasma concentration versus time curve from zero to infinity (AUCi)

    Descriptive Statistics

    Time frame: 72 hours

  2. Time of the maximum measured plasma concentration (Tmax)

    Descriptive Statistics

    Time frame: 72 hours

07

Study locations

1 site
  • Cliantha Research Limited
    Ahmedabad, Gujarat 380 051, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jun 2025, 0 months.

Of 21 industry-sponsored phase 1 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 2 months of starting (the median); a quarter within 1 and three quarters within 7. This study's 0 months is below that.

Counting every sponsor, half of 35 studies reached it within 9 months; a quarter within 2 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Aug 1, 2025
StartActual
May 26, 2025
Primary completionActual
Jun 6, 2025
CompletionActual
Jul 17, 2025
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07098585
Responsible party
Sponsor
First posted
Aug 1, 2025
Start date
May 26, 2025
Primary completion
Jun 6, 2025
Completion
Jul 17, 2025
Last update
Aug 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion